CN114099559A - Application of hypericum japonicum extract in preparation of anti-influenza B virus medicine - Google Patents
Application of hypericum japonicum extract in preparation of anti-influenza B virus medicine Download PDFInfo
- Publication number
- CN114099559A CN114099559A CN202111495701.3A CN202111495701A CN114099559A CN 114099559 A CN114099559 A CN 114099559A CN 202111495701 A CN202111495701 A CN 202111495701A CN 114099559 A CN114099559 A CN 114099559A
- Authority
- CN
- China
- Prior art keywords
- hypericum japonicum
- extract
- influenza
- virus
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000219416 Hypericum japonicum Species 0.000 title claims abstract description 51
- 239000000284 extract Substances 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 208000037798 influenza B Diseases 0.000 title claims description 12
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 7
- 239000011347 resin Substances 0.000 claims abstract description 4
- 229920005989 resin Polymers 0.000 claims abstract description 4
- 239000003480 eluent Substances 0.000 claims abstract description 3
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 18
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims description 9
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 9
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 9
- 239000006286 aqueous extract Substances 0.000 claims description 9
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 9
- 229960001285 quercetin Drugs 0.000 claims description 9
- 235000005875 quercetin Nutrition 0.000 claims description 9
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims description 8
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 claims description 8
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 claims description 8
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 claims description 8
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims description 8
- 229930182470 glycoside Natural products 0.000 claims description 6
- 150000002338 glycosides Chemical class 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 claims description 5
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 claims description 5
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 claims description 5
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 claims description 5
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 241000713196 Influenza B virus Species 0.000 abstract description 15
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 abstract description 7
- 229960002194 oseltamivir phosphate Drugs 0.000 abstract description 7
- 239000002775 capsule Substances 0.000 abstract description 5
- 239000000178 monomer Substances 0.000 abstract description 5
- 230000001754 anti-pyretic effect Effects 0.000 abstract description 4
- 239000002221 antipyretic Substances 0.000 abstract description 4
- 239000013641 positive control Substances 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract description 2
- 241001060350 Acalypha Species 0.000 abstract 1
- 230000008014 freezing Effects 0.000 abstract 1
- 238000007710 freezing Methods 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 6
- 241000712431 Influenza A virus Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000001932 seasonal effect Effects 0.000 description 3
- 241000227287 Elliottia pyroliflora Species 0.000 description 2
- 241000753651 Influenza B virus (B/Lee/1940) Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000219000 Populus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000312 effect on influenza Effects 0.000 description 2
- OZBAVEKZGSOMOJ-MIUGBVLSSA-N glycitin Chemical compound COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZBAVEKZGSOMOJ-MIUGBVLSSA-N 0.000 description 2
- 230000001309 inhibitory effect on influenza Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000725618 Duck hepatitis B virus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000598860 Garcinia hanburyi Species 0.000 description 1
- XJTZHGNBKZYODI-UHFFFAOYSA-N Glycitin Natural products OCC1OC(Oc2ccc3OC=C(C(=O)c3c2CO)c4ccc(O)cc4)C(O)C(O)C1O XJTZHGNBKZYODI-UHFFFAOYSA-N 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- RQBBFKINEJYDOB-UHFFFAOYSA-N acetic acid;acetonitrile Chemical compound CC#N.CC(O)=O RQBBFKINEJYDOB-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- -1 bispyridone Natural products 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229940117709 gamboge Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of hypericum japonicum thunb extract in preparing a medicament for resisting influenza B virus. The hypericum japonicum extract is prepared by adsorbing a hypericum japonicum medicinal material water extract by using macroporous resin, sequentially eluting by using water, 20% ethanol and 60% ethanol, collecting 60% ethanol eluent, concentrating, freezing and drying. The hypericum japonicum thunb extract has stronger effect of inhibiting influenza B virus, and the effect of the hypericum japonicum thunb extract is obviously better than that of main monomer components and positive control drugs of the copperleaf antipyretic capsule and oseltamivir phosphate.
Description
Technical Field
The invention relates to application of a traditional Chinese medicine extract, in particular to a hypericum japonicum effective part and medicinal application thereof.
Background
Influenza B virus (influenza B virus) is a single-stranded negative-strand RNA virus of the orthomyxoviridae family, which causes local outbreaks or seasonal epidemics of influenza each year in conjunction with influenza a virus, and the major susceptible population is youngsters and the elderly between 5 and 19 years of age. The seasonal influenza B virus peak period is longer than the duration of influenza A virus, the infection number of certain influenza seasons is even more than that of influenza A virus, such as the seasonal influenza in 2017 and 2018, more than 60% of influenza infection cases in Europe are caused by the influenza B virus, and in addition, one third of the burden of influenza-related diseases in the world every year is caused by the influenza B virus. Due to the high antigenic variability of influenza viruses and the generation of drug resistance, the prevention and treatment effects of the current influenza vaccines and antiviral drugs on the influenza B viruses are not ideal. In addition, in the current development aspect of anti-influenza virus medicines, anti-influenza A virus medicines are mostly researched, and the research on influenza B virus medicines is less. At present, some medicaments have proved to have inhibitory effect on influenza A virus but have no effect or poor effect on influenza B virus, for example, medicaments such as amantadine medicaments, copperflower antipyretic capsules and the like only have the effect on influenza A virus and do not have the inhibitory effect on influenza B virus. The traditional Chinese medicine shows exact curative effect in the aspect of preventing and treating viral infectious diseases, and has small toxic and side effects, so that the development of a better anti-influenza B virus medicine is very significant on the basis of abundant traditional Chinese medicine treasury.
Hypericum japonicum thunb, which is a whole plant of hypericum japonicum thunb of hypericum genus of gamboge family, has the effects of clearing heat, promoting diuresis, detoxifying, removing blood stasis, reducing swelling and the like, and has the main components of flavone, bispyridone, phloroglucinol, volatile oil, organic acid and the like. Although the invention patent CN202011106518.5 and the literature disclose the function of hypericum japonicum extract in resisting new coronavirus and duck hepatitis B virus, the structural properties of different viruses are different, so that whether hypericum japonicum has the inhibiting effect on other viruses or not can not be deduced.
Disclosure of Invention
The invention discloses a hypericum japonicum effective part extract and application thereof in preparing anti-influenza B virus medicines.
The extract is prepared by the following method:
adsorbing the aqueous extract of hypericum japonicum thunb by using D101 macroporous resin, eluting by using 8-12 times of column volume of water, 8-12 times of 20% ethanol and 3-7 times of column volume of 60% ethanol in sequence, collecting 60% ethanol eluent, concentrating, and freeze-drying to obtain the hypericum japonicum thunb extract.
The aqueous extract of hypericum japonicum medicinal materials can be prepared by the following method: decocting herba Hyperici Japonici at 100 deg.C for 0.5 hr at a ratio of material to liquid of 1:12, extracting for three times, and mixing filtrates to obtain water extractive solution of herba Hyperici Japonici.
The herba Hyperici Japonici extract contains six compounds of dihydroquercetin-7-O-rhamnoside, dihydroquercetin, isoquercitrin, quercitrin, herba Hyperici Japonici glycoside and quercetin, and the total content is more than 25% of herba Hyperici Japonici extract.
The hypericum japonicum effective part extract disclosed by the invention has stronger effect of inhibiting influenza B virus, and the effect is stronger than that of each main monomer component, even stronger than that of positive control drugs of honeysuckle antipyretic capsule and oseltamivir phosphate.
Drawings
FIG. 1 is an HPLC chromatogram of aqueous extract of Hypericum japonicum Thunb, effective fraction of Hypericum japonicum Thunb and mixed reference; in the figure, 1 is dihydroquercetin-7-O-rhamnoside, 2 is dihydroquercetin, 3 is isoquercitrin, 4 is quercitrin, 5 is hypericum japonicum glycosides, and 6 is quercetin;
FIG. 2 is a bar graph of the anti-influenza B virus activity of hypericum japonicum extract and its major monomeric compounds at a concentration of 25. mu.g/mL; in the figure, 1 is hypericum japonicum aqueous extract, 2 is hypericum japonicum effective part, 3 is quercetin, 4 is quercetin, 5 is hypericum japonicum glycoside, 6 is isoquercitrin, 7 is dihydroquercetin-7-O-rhamnoside, 8 is dihydroquercetin, 9 is copperflower antipyretic capsule, and 10 is oseltamivir phosphate.
The specific implementation mode is as follows:
example 1: preparation of aqueous extract of herba Hyperici Japonici
Taking 500g of herba Hyperici Japonici dry medicinal material, adding 8 times, 10 times and 12 times of water, decocting at 60 deg.C, 80 deg.C and 100 deg.C for 0.5 hr, 1.0 hr and 1.5 hr for 3 times, mixing, and filtering to obtain herba Hyperici Japonici water extractive solution. Wherein the preparation method comprises extracting at 100 deg.C with 12 times of water for 0.5 hr, concentrating, and drying to obtain herba Hyperici Japonici water extract.
Example 2: preparation of effective part of hypericum japonicum
Taking 500g of hypericum japonicum dry medicinal material, adding 12 times of water, decocting and extracting for 0.5h at 100 ℃, extracting for three times, and combining filtrates to obtain hypericum japonicum water extract. Adsorbing the water extract with D101 macroporous resin, eluting with 8-12 times column volume of water and 20% ethanol respectively, eluting with 3-7 times column volume of 60% ethanol, collecting 60% ethanol eluate, concentrating, and freeze drying to obtain herba Hyperici Japonici effective part.
Example 3: chemical composition analysis of effective part of hypericum japonicum
240mg of the hypericum japonicum thunb extract prepared in the example 2 is taken and dissolved in 5% methanol, and the chemical components of the hypericum japonicum thunb extract are analyzed by adopting a liquid chromatography-mass spectrometry (LC-MS) method, wherein the liquid chromatography condition is a diode array detector; the chromatographic column is an octadecyl bonded silica gel packed column with the diameter of 5 mu m and the diameter of 4.6 multiplied by 250 mm; a flow rate of about 1.0 mL/min; the mobile phase was a mixed solution of 0.1% acetic acid-acetonitrile (74: 26).
The analysis result shows that the effective part of hypericum japonicum contains dihydroquercetin-7-O-rhamnoside, dihydroquercetin, isoquercitrin, quercitrin, hypericum japonicum glycoside and quercetin, and the content is more than 25%.
Example 5: evaluation of anti-influenza B virus activity of effective part of hypericum japonicum
1. Experimental Material
1.1. Cells and viruses
Dog kidney cells (MDCK cells), provided by the stress laboratory poplar peak researcher laboratory in respiratory disease countries. Strains B/Lee/1940, B/Guangzhou/19/2016 (Yamagata-like), B/Guangzhou/0215/2012 (Victoria-like) are supplied by the national stress labs Poplar peak researcher laboratories for respiratory diseases.
1.2. Medicine
Aqueous extracts of hypericum japonicum were prepared as described in example 1. The effective part of hypericum japonicum is prepared in example 2. The Lianhua Qingwen capsule is provided by Shijiazhuang Ling pharmaceutical industry GmbH. Oseltamivir phosphate is available from sigma aldrich trade ltd with a purity of 99% or more. Quercetin, glycitin, and Isoquercitrin were all purchased from Shanghai Shidande Standard technology services, Inc. The dihydroquercetin-7-O-rhamnoside and dihydroquercetin are purchased from Cheno Biotechnology GmbH of Zhongshan city, and have purity of 98% or more.
2. Experimental methods
Experiment of anti-influenza B virus activity of the medicine: MDCK cells were digested with trypsin and then treated at 3X 104Cells/well were seeded into 96 wells at 100. mu.L/well at 37 ℃ in 5% CO2Culturing in incubator for 24 hr, discarding supernatant, and adding 100TCID per well50Adding DMEM diluted herba Hyperici Japonici sample, monomer compound or positive control drug into influenza B virus culture medium, setting virus control group and cell control group, setting 3 multiple wells in each group, and culturing at 37 deg.C with 5% CO2The incubator is incubated for 2-3 days, the supernatant is discarded, and MTT is added for continuous culture for 4 h. MTT was then discarded and dissolved by adding 200. mu.L DMSO per well. The absorbance at 490nm was read with a microplate reader. Each experiment was repeated 3 times in parallel.
Viral inhibitory rate (drug group OD)490Value-virome OD490Value)/(cell control OD490Value-virome OD490Value) × 100%.
3. Results of the experiment
The method for detecting herba Hyperici Japonici extract by MTT assayThe results of the activity of the MDCK cells against the influenza B virus (B/Lee/1940) are shown in a table 1, and the results show that the hypericum japonicum aqueous extract has the obvious effect of inhibiting the influenza B virus (B/Lee/1940), and the activity of the hypericum japonicum aqueous extract is equivalent to that of oseltamivir phosphate; after being prepared, the effective part of hypericum japonicum can inhibit the half Inhibitory Concentration (IC) of influenza B virus50) Is about one time smaller than the water extract of the osletamivir phosphate, and the activity of the osletamivir phosphate is superior to that of the positive drug oseltamivir phosphate.
TABLE 1 anti-influenza B virus (B/Lee/1940) activity of hypericum japonicum extract
In order to compare the antiviral activities of hypericum japonicum extract, the effective part and the main monomer compound, MTT experiments are adopted to detect the anti-influenza B virus strain activity of the medicines at the concentration of 25 mu g/mL, the result is shown in figure 2, and the result shows that the hypericum japonicum effective part has obvious inhibitory action on different influenza B viruses at the same medicine concentration (25 mu g/mL), and the action effect is superior to that of water extract and main monomer components (quercetin, hyperin, isoquercitrin, dihydroquercetin-7-O-rhamnoside and dihydroquercetin) contained in the water extract.
The research results show that the hypericum japonicum effective part extract mainly contains dihydroquercetin-7-O-rhamnoside, dihydroquercetin, isoquercitrin, quercitrin, hypericum japonicum glycoside and quercetin, can effectively inhibit the influenza B virus, and has in vitro anti-influenza B virus activity obviously stronger than that of oseltamivir phosphate.
Claims (3)
1. The application of hypericum japonicum thunb extract in preparing anti-influenza B virus medicines is characterized in that the hypericum japonicum thunb extract is prepared by the following method: adsorbing the aqueous extract of hypericum japonicum thunb by using D101 macroporous resin, eluting by using 8-12 times of column volume of water, 8-12 times of 20% ethanol and 3-7 times of column volume of 60% ethanol in sequence, collecting 60% ethanol eluent, concentrating, and freeze-drying to obtain the hypericum japonicum thunb extract.
2. Use according to claim 1, characterized in that: the medicinal water extract of hypericum japonicum is prepared by the following method: decocting herba Hyperici Japonici at 100 deg.C for 0.5 hr at a ratio of material to liquid of 1:12, extracting for three times, and mixing filtrates to obtain water extractive solution of herba Hyperici Japonici.
3. Use according to claim 1 or 2, characterized in that: the hypericum japonicum extract contains six compounds of dihydroquercetin-7-O-rhamnoside, dihydroquercetin, isoquercitrin, quercitrin, hypericum japonicum glycoside and quercetin, and the total content is more than 25% of the hypericum japonicum extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111495701.3A CN114099559A (en) | 2021-12-09 | 2021-12-09 | Application of hypericum japonicum extract in preparation of anti-influenza B virus medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111495701.3A CN114099559A (en) | 2021-12-09 | 2021-12-09 | Application of hypericum japonicum extract in preparation of anti-influenza B virus medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114099559A true CN114099559A (en) | 2022-03-01 |
Family
ID=80364633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111495701.3A Pending CN114099559A (en) | 2021-12-09 | 2021-12-09 | Application of hypericum japonicum extract in preparation of anti-influenza B virus medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114099559A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105106252A (en) * | 2015-08-13 | 2015-12-02 | 华润三九医药股份有限公司 | Method for extracting and separating flavonoid compounds from hypericum japonicum |
| CN112263598A (en) * | 2020-10-17 | 2021-01-26 | 中山大学 | Herba Hyperici Japonici extract and its application in preparing medicine for resisting novel coronavirus |
-
2021
- 2021-12-09 CN CN202111495701.3A patent/CN114099559A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105106252A (en) * | 2015-08-13 | 2015-12-02 | 华润三九医药股份有限公司 | Method for extracting and separating flavonoid compounds from hypericum japonicum |
| CN112263598A (en) * | 2020-10-17 | 2021-01-26 | 中山大学 | Herba Hyperici Japonici extract and its application in preparing medicine for resisting novel coronavirus |
Non-Patent Citations (4)
| Title |
|---|
| ENKHTAIVAN GANSUKH: "New insights into antiviral and cytotoxic potential of quercetin and its deriva‐", 《 FOOD CHEMISTRY》 * |
| 刘妮等: "田基黄体内抗甲3型流感病毒作用研究", 《中药材》 * |
| 欧淑芬等: "田基黄成分及药理应用研究进展", 《药学研究》 * |
| 碳硼酸 病毒学界: "槲皮素衍生物有望作为流感病毒抑制剂", 《微信》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Extraction of bio-active components from Rhodiola sachalinensis under ultrahigh hydrostatic pressure | |
| CN108445114B (en) | Method for screening trace neuraminidase inhibitor in honeysuckle | |
| CN101259159A (en) | Preparation of alhagi sparsifolia total flavones and uses thereof | |
| CN103099838A (en) | Anti-hepatitis B virus composition taken from fresh dandelion and application of anti-hepatitis B virus composition in preparation of anti-hepatitis B virus drug | |
| CN108670973B (en) | Sarcandra glabra anti-influenza virus active extract and preparation method thereof | |
| CN101129455B (en) | Sophora extractive and method of preparing the same and application of the same | |
| CN103160549A (en) | Method of preparing, separating and purifying baicalein and wogonin by endogenous enzymatic hydrolysis of baicalin and wogonoside in scutellaria | |
| CN104370871B (en) | The mouth diphenylene ketone oxide class separated from Swertia punicea Hemsl. and the application of suppression hepatitis B virus | |
| CN101234147B (en) | Method of preparing total flavones of tropaeolum for injections | |
| CN102283898A (en) | Flos caryophyllata leaf extract and preparation method thereof | |
| CN104382968B (en) | Extraction method of andrographolide, andrographolide pharmaceutical composition and application | |
| CN114099559A (en) | Application of hypericum japonicum extract in preparation of anti-influenza B virus medicine | |
| CN100443493C (en) | Process of preparing burdock glucoside and glucosidgen thereof | |
| CN1962650A (en) | Process for preparing high-purity dehydrated andrographolide | |
| CN103113196B (en) | Glechoma longituba phenol, and preparation method and application thereof | |
| CN112618584A (en) | Application of four-tile extract in preparing medicine for resisting hepatitis B virus and/or preventing and treating hepatitis B | |
| CN101036684B (en) | Isatis-Root extractive and the purifying method and the medicine combination | |
| CN103351411B (en) | The method for separating and preparing of five kinds of Phenylpropanoid Glycosides glycoside monomeric compounds in Root of Common Lamiophlomis | |
| CN102030789A (en) | Method for preparing special component of traditional Chinese medicine Indian trumpetflower seed, namely Oroxin B | |
| CN102675298B (en) | Method for extracting and preparing silymarin from polygonum capitatum herb | |
| CN103393738B (en) | Traditional Chinese medicine composition for preventing influenza A viruses H1N1 | |
| CN102908373A (en) | Extraction method of total eoumarins in Chinese medicament common cnidium fruit | |
| CN101972289A (en) | Method for extracting and enriching general flavone in aerial part of Yunnan bupleurum with antiviral activity | |
| CN102603763A (en) | Method for extracting lignans compounds from Radix Clematidis and application | |
| CN109942650B (en) | Extraction method and medical application of prunus humilis glycoside |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220301 |
|
| RJ01 | Rejection of invention patent application after publication |